The Importance of Early Detection: How Early Diagnosis Saves Lives

Last updated 14 July 2026

Most people do not find a lump in a clinic. They find it in the shower, or while putting on a bra, or when a shirt suddenly feels tight in one place. There is a pause, a second check, then a decision that happens almost without thinking: wait a bit and see. That pause, repeated across thousands of Malaysian households every month, is one of the quietest and costliest habits in our health system.

This article is not a screening guide. We cover that separately in our full guide to early cancer detection and screening in Malaysia. This one is about the part almost nobody explains: what actually happens after something suspicious is found, and why specialist care at that point matters enormously.

Why the first weeks matter so much

Malaysia has a stage problem. The Malaysia National Cancer Registry Report 2017-2021, published by the Ministry of Health, found that among cancers with a recorded stage, 64.8 per cent were already at Stage 3 or Stage 4 when they were diagnosed. The registry adds a caveat worth respecting, that a stage was documented for only about half of registered cases, but the pattern holds across every major cancer site it reports. Roughly two out of every three Malaysians who hear the word cancer hear it late.

Stage is not a technicality. It shapes which treatments are possible and how well they are likely to work. Early detection does not guarantee a cure, and it would be wrong to pretend otherwise: some cancers behave aggressively even when small. But for many of the common ones in Malaysia, being found at Stage 1 rather than Stage 4 changes the whole conversation, from one about control to one about cure.

You found something. Now what?

Here is how the pathway works. It involves waiting, but each step exists for a reason.

Step	What happens	What it can tell you
1. First visit	GP, klinik kesihatan or panel clinic. History, examination, basic bloods.	Can flag that something needs looking into. Cannot confirm cancer.
2. Referral	To a hospital specialist: surgeon, gynaecologist, gastroenterologist or respiratory physician.	Gets you to someone who can order and act on the right tests.
3. Imaging	Ultrasound, mammogram, CT, MRI, endoscopy or colonoscopy.	Shows where an abnormality is and whether it looks worrying. Still not a diagnosis.
4. Biopsy	A small tissue sample taken with a needle, through a scope, or during surgery.	This is the step that confirms or rules out cancer.
5. Histopathology	A pathologist examines the sample under a microscope and runs further tests on it.	Whether it is cancer, what type, and how aggressive it looks.
6. Staging	Further scans, sometimes surgery, to see how far the disease has travelled.	Determines treatment options and prognosis.

Notice what is missing: there is no shortcut. No single blood test replaces steps 4 and 5. Scans raise suspicion. Tissue settles it.

What a biopsy actually is

A biopsy is a procedure that removes a small piece of tissue so it can be examined under a microscope. That is the whole of it, and it is not optional. The Ministry of Health’s Clinical Practice Guidelines on the Management of Breast Cancer require what they call triple assessment before a breast cancer is diagnosed: clinical examination, imaging, and pathology, meaning tissue or cells looked at under a microscope. Two out of three is not a diagnosis. The same guideline sets a clock on the front end, too: a woman over 35 with breast signs or symptoms should be referred to a breast or surgical clinic within two weeks.

In practice a biopsy is often far less dramatic than people imagine. Many are done with a needle under local anaesthetic in an outpatient setting, take minutes, and leave nothing more than a plaster and a bruise. Some are taken during an endoscopy or colonoscopy, while you are already sedated for the scope. Only some require a formal operation.

Two fears come up again and again in Malaysian clinics.

“Won’t cutting into it make the cancer spread?” This belief is common and it is not supported by the evidence. Biopsies are a routine, standard part of cancer diagnosis worldwide precisely because they are safe enough to be worth doing. The far greater risk is the delay caused by refusing one.

“If I don’t know, it can’t hurt me.” It can. Cancer does not pause while you decide. Every week spent on wait-and-see, or on traditional remedies taken instead of a proper diagnosis rather than alongside proper care, is a week the disease has to itself. Many lumps turn out not to be cancer at all. A biopsy is often the fastest route to relief, not to bad news.

Waiting for the result is hard, and it is normal to feel worse during that wait than at any other point. It usually takes several days to a couple of weeks, because the tissue must be processed, cut, stained and read carefully.

What a blood test can and cannot tell you

Tumour markers such as CA-125, AFP, PSA and CEA do not diagnose cancer, and they are not screening tests for people without symptoms.

Malaysia’s own clinical guidance says so. The Ministry of Health’s Clinical Practice Guidelines on the Management of Colorectal Carcinoma state that the use of CEA is “exclusively confined for monitoring and follow-up” and that it “should not be used as a screening method”, because a normal level does not mean the cancer is absent. Read that twice. The national guideline is explicit that this marker must not be used to screen.

Ovarian cancer is the clearest example of the harm. CA-125 is often assumed to be an ovarian cancer test. Yet ovarian cancer appears nowhere in Malaysia’s national screening programmes, which cover breast, cervical, colorectal and oral cancer and nothing else. The reason is evidence. The UK Collaborative Trial of Ovarian Cancer Screening, the largest study ever done on the question, randomised more than 200,000 women to annual CA-125 testing, annual ultrasound, or no screening. Its long-term results, published in The Lancet in 2021, found that neither approach reduced deaths from ovarian cancer. A CA-125 result can help a doctor assess a woman who already has unexplained symptoms. It is not a yearly check that tells a healthy woman she is clear.

So what are tumour markers for? Mostly for people who already have a confirmed cancer: estimating prognosis, tracking whether a treatment is working when measured repeatedly over time, and watching for recurrence after treatment ends. That is real, everyday oncology. It is simply not diagnosis.

What a result actually means. A normal tumour marker result does not mean cancer is absent, and it can give false reassurance that delays the tests which would have found something. An abnormal result does not mean cancer is present, and it can lead to months of anxiety and further investigation for a condition you do not have. If tumour marker testing is offered to you, the question worth asking your doctor is a simple one: what would this result change?

Why staging decides almost everything

Once cancer is confirmed, the next question is not “what treatment do I want” but “how far has it gone”. Staging answers that.

Most cancers are staged using the TNM system: T for the size and extent of the primary tumour, N for whether nearby lymph nodes are involved, and M for whether the disease has spread to distant parts of the body. Those three letters are grouped into the familiar Stage 1 to Stage 4. TNM is what Malaysian practice runs on: the national guidelines for both breast and colorectal cancer require histopathology to be reported against it, so that every hospital in the country is describing the same disease in the same language.

Staging scans are therefore not bureaucratic delay. A Stage 2 breast cancer and a Stage 4 breast cancer can feel identical to the patient, yet they are treated completely differently. Getting the stage wrong means getting the treatment wrong.

What specialist oncology care actually involves

People often picture cancer treatment as one doctor and one drug. Modern cancer treatment looks nothing like that.

A team, not a single doctor

Serious cancer care runs through a multidisciplinary meeting, sometimes called a tumour board. Surgeons, medical oncologists, radiation oncologists, radiologists, pathologists and specialist nurses look at the same case together and agree a plan. This is not a foreign import: Malaysia’s national guidelines for breast cancer say a multidisciplinary team approach should be used to improve clinical outcomes, and the colorectal guideline says the same for advanced disease. Sequence is often the hard part. Should chemotherapy come before surgery to shrink the tumour, or after it to mop up? A doctor working alone is more likely to reach for the tool they personally know best.

The three pillars

• Surgical oncology: removing the tumour and, where needed, the lymph nodes around it.
• Medical oncology: systemic treatment that travels through the bloodstream, including chemotherapy, hormone therapy, targeted therapy and immunotherapy.
• Radiation oncology: precisely aimed radiation to destroy cancer cells in a defined area, used to cure, to reduce the chance of recurrence, or to relieve symptoms.

Many cancers need two or all three, in a particular order.

Precision medicine: what tumour markers are actually for

This is the useful contrast. The same biology that fails as a screening test becomes powerful once cancer is confirmed and tissue is available.

Biomarker testing, also called tumour profiling or molecular testing, looks for specific proteins and genetic changes inside the cancer itself. It is standard practice here, not an experimental extra. The Malaysian breast cancer guideline requires that oestrogen and progesterone receptor status be assessed in every case of breast cancer, and that HER2 testing be performed on every invasive specimen, because those results decide whether a woman should receive hormone therapy, or trastuzumab, or neither. The same logic runs through lung and colorectal cancer, where a mutation found in the tumour can identify a patient likely to benefit from a targeted drug, and can equally spare someone a treatment with no realistic chance of helping them.

Note the difference. Markers used on a healthy population to hunt for hidden cancer: unreliable. Markers used on a confirmed tumour to choose the right drug: one of the most important advances in oncology this century.

Supportive and palliative care, from the start

Palliative care is widely misunderstood in Malaysia as something that begins when treatment stops. It is not. Good supportive care runs alongside active treatment: controlling pain and nausea, protecting nutrition, managing fatigue, and supporting the mental health of the patient and the family. It exists to make treatment tolerable enough to finish, which is itself part of making treatment work.

Time matters at every step

The conversation about early detection usually stops at screening. But a diagnosis is not a single moment, it is a chain, and the chain can break anywhere. Consider where weeks quietly disappear: the months spent deciding whether the lump is worth mentioning, the wait for a referral, the wait for a scan slot, the wait for the biopsy, the wait for the pathology report, the wait for the first oncology consultation, the wait to start treatment. Each delay is defensible on its own. Added together, they can turn a Stage 2 cancer into a Stage 3 one.

So the question to ask at every appointment is not only “what is the plan” but “when, and who is chasing it”. Ask for timelines. Ask who to call if a result has not come back. Ask whether anything can be done in parallel rather than one after another. Being a persistent patient is not rudeness. In cancer care it is self-defence.

Where cancer is treated in Malaysia

Cancer care here runs on two tracks, and it is worth understanding both.

The government system treats most cancer patients in Malaysia, and the cost is heavily subsidised. Entry is by referral, usually from a klinik kesihatan. The main centres offering both chemotherapy and radiotherapy include Institut Kanser Negara (IKN) in Putrajaya, Hospital Kuala Lumpur, Hospital Pulau Pinang, Hospital Sultan Ismail in Johor Bahru, Hospital Umum Sarawak, Sabah Women and Children’s Hospital, and the university hospitals: Universiti Malaya Medical Centre, PPUKM and Hospital Universiti Sains Malaysia in Kubang Kerian. Waiting times can be long. The care is not lesser for being subsidised.

Private care is faster to access and you pay for it, from your own pocket or through insurance. It ranges from large hospital groups with oncology departments to smaller specialist practices. Curie Oncology, at Cengild Medical Center Nexus in Bangsar South, is one such practice, with a team of clinical oncologists who plan and coordinate care from diagnosis through treatment and follow-up.

The Malaysian Oncological Society maintains a directory of cancer centres in every state, which is the most complete list available and worth checking for something near you.

Whichever route you take, ask directly: who will be on my team, what is the plan, what are the alternatives, what will it cost, and can I get a second opinion. A good oncologist will not be offended by any of those questions.

If you are waiting for a result right now

Two things are worth holding on to. Most lumps, shadows and abnormal findings are not cancer. And if it is cancer, knowing is better than not knowing, at every stage, without exception. The people who do best are rarely the lucky ones. They are the ones who went in early, agreed to the biopsy, and kept the process moving.